Climb Bio, Inc. (CLYM)

Climb Bio, Inc. stock has increased significantly in the past six months. Key events impacting the stock price include FDA Fast Track Designation for Budoprutug, clinical trial progress and data readouts, financial results indicating a cash balance of $160.7 million at the end of 2025, analyst coverage with a consensus "Buy" rating, and the acquisition of Tenet Medicines along with a $120 million private investment.

As a clinical-stage biotechnology company, Climb Bio, Inc. does not currently have commercialized products or services, therefore, the concept of demand seasonality is not applicable.

Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases. The company's pipeline is centered on monoclonal antibody product candidates designed to modulate B-cell biology. Its major product candidates include Budoprutug, an anti-CD19 monoclonal antibody in Phase 2 clinical trials for pMN and Phase 1b/2a trials for ITP and SLE, and CLYM116, an anti-APRIL monoclonal antibody in Phase 1 healthy volunteer studies for IgAN and other B-cell mediated diseases.

Climb Bio, Inc. is headquartered in Wellesley Hills, Massachusetts, United States. The company has a global clinical development presence, with 20 regulatory clearances to conduct clinical trials and 45 trial sites globally for its budoprutug and CLYM116 programs, including regulatory clearance for its SLE investigational new drug application in China.

Information directly pertaining to Climb Bio, Inc.'s brand reputation is not explicitly available. The news and analyst coverage primarily focus on the company's clinical development progress, financial updates, and stock performance. The positive analyst ratings and the significant increase in stock price suggest a generally favorable perception within the investment community.

Climb Bio, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Institutional investors own approximately 53.64% to 56.22% of the company's stock. Insiders hold around 24.12% of the stock, and public companies and retail investors own approximately 2.58% to 36%. Major institutional owners include Ra Capital Management, L.p., MPM Oncology Impact Management LP, and Price T Rowe Associates Inc /md/.